id	等位基因	注释文本
1241	TT	Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1240	CT	Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1239	CC	Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

id	证据的ID	总结
2336	1449732020	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.
2335	1449162040	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.
2334	1449161763	Genotype CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CT + TT.
2333	1448994776	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.
2332	1448568402	Genotype CT is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype CC.
2331	1448262697	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
2330	1448124838	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.
2329	1448124661	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.
2328	1448124239	Genotype CT is associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
2327	1448123237	Genotypes CT + TT is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.
2326	1450954660	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
2325	1450953025	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele C.
2324	1447945626	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.
2323	PA166109594	Annotation of CPIC Guideline for capecitabine and DPYD

id	类型	评论
1371	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1370	Update	Added CPIC function and modified text.
1369	Update	Attached CPIC guideline and removed override.
1368	Update	CA for capecitabine and ADR evidence; level 1A since included in CPIC guideline as normal function variant
1367	Create	Created

最新招商产品更多>>